CI
PTGX icon

Cavalier Investments’s Protagonist Therapeutics PTGX Stock Holding History

Cavalier Investments’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,252
Closed -$1.21M – 80
2024
Q4 		$1.21M Buy
31,252
+1,296
+4% +$56.5K 0.4% 41
2024
Q3 		$1.35M Buy
+29,956
New +$1.21M 0.41% 55

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cavalier Investments's PTGX Position: Q1 2025 in Review

Cavalier Investments sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 31,252 shares — an estimated $1.21M sold.

Cavalier Investments first reported a position in PTGX in Q3 2024 and held it in 2 quarters. The position peaked at $1.35M in Q3 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Cavalier Investments reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cavalier Investments sold 31,252 Protagonist Therapeutics shares in Q1 2025, an estimated $1.21M.
  • Cavalier Investments first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 2 quarters.
  • Cavalier Investments's Protagonist Therapeutics position peaked at $1.35M in Q3 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Cavalier Investments's 13F filing for Q1 2025, filed 24 Apr 2025.